Depakote (divalproex sodium) treats bipolar disorder by calming the excessive brain activity that drives manic episodes. It works through several mechanisms at once: it increases levels of a brain chemical called GABA that has a natural calming effect, it reduces the rapid-fire signaling of sodium channels in nerve cells, and it appears to dampen certain cell-signaling pathways that become overactive during mania. The combined result is a stabilizing effect on mood, particularly during the intense highs of a manic episode.
What Depakote Is Approved to Treat
The FDA approved Depakote specifically for treating manic episodes associated with bipolar disorder. This means it’s indicated for the acute highs, including full manic episodes and mixed episodes (where symptoms of mania and depression overlap). It is not FDA-approved for the depressive phase of bipolar disorder, though some clinicians prescribe it off-label as a long-term mood stabilizer to prevent future episodes.
The key clinical trials that established its effectiveness were three-week studies involving hospitalized patients experiencing acute mania. The FDA label notes that effectiveness beyond three weeks of use for mania has not been demonstrated in controlled trials, though many people take it long-term as maintenance therapy based on clinical experience.
How It Stabilizes the Brain During Mania
Mania involves a kind of electrical and chemical overexcitement in the brain. Depakote addresses this on multiple fronts. Its best-understood mechanism involves GABA, the brain’s primary “braking” chemical. Depakote boosts GABA levels by blocking the enzyme that normally breaks it down and by stimulating the enzyme that produces it. More GABA means more inhibitory signaling, which slows down the runaway neural activity characteristic of mania.
Depakote also blocks voltage-gated sodium channels. These channels are responsible for allowing nerve cells to fire electrical signals. By partially blocking them, Depakote makes it harder for neurons to fire in rapid, sustained bursts. This is the same basic mechanism that makes it useful as an anti-seizure medication, since seizures and mania both involve excessive, synchronized brain activity.
There’s also evidence that Depakote affects intracellular signaling cascades, including pathways involving protein kinase C and others involved in neuronal growth and survival. These deeper effects on cell signaling may explain why Depakote can take time to reach its full stabilizing potential and why it helps prevent future episodes in some people.
How Effective It Is Compared to Lithium
In the landmark trial published in JAMA comparing Depakote, lithium, and placebo for acute mania, both active medications performed similarly. About 48% of patients on Depakote improved by at least 50%, compared to 49% on lithium and just 25% on placebo. The dropout rate due to the medication not working was also lower with Depakote (30%) than with placebo (51%).
These numbers mean Depakote roughly doubles your chances of significant improvement compared to no treatment. It’s considered a first-line option for acute mania alongside lithium, and the choice between them often comes down to side effect profiles, individual response, and other health factors. Some people respond better to one than the other, and there’s no reliable way to predict which will work best for a given person beforehand.
How Quickly It Works
Most people begin noticing some reduction in manic symptoms within the first one to two weeks, though the pivotal trials measured outcomes at three weeks. Clinicians sometimes use a “loading dose” strategy to speed things up, starting at a higher dose (around 20 mg per kilogram of body weight per day) to reach effective blood levels more quickly. This approach can produce noticeable effects within a few days rather than waiting for a gradual dose increase to build up over weeks.
Your doctor will monitor your blood levels to make sure the medication reaches a therapeutic concentration, generally keeping levels below 100 micrograms per milliliter. Blood draws are routine with Depakote, particularly early in treatment, to ensure the dose is effective without being excessive.
Weight Gain and Metabolic Effects
Weight gain is one of the most common and frustrating side effects. In a long-term study of patients on divalproex sodium, about 63% experienced weight gain. The average amount gained at peak weight was 19% of the person’s starting body weight, which for someone weighing 150 pounds translates to roughly 28 pounds. The range was wide, from about 5% to over 56% of initial body weight, and the average time to reach maximum weight gain was about 44 months.
Higher doses correlated with more weight gain. Patients who gained weight were on an average daily dose of about 1,791 mg, compared to 1,429 mg in those who didn’t gain. This side effect can be significant enough to affect treatment decisions, especially for people already managing metabolic health concerns. Regular monitoring of weight, blood sugar, and cholesterol is typical during long-term use.
Other Side Effects to Watch For
Depakote carries FDA black box warnings for three serious risks: liver damage, inflammation of the pancreas, and harm to a developing fetus.
Liver toxicity is most concerning in the first six months of treatment. Symptoms to watch for include unusual fatigue, weakness, facial swelling, loss of appetite, and vomiting. Liver function tests are performed before starting the medication and at regular intervals afterward, especially during those early months. Importantly, blood tests don’t always catch liver problems, so reporting any new symptoms matters.
Pancreatitis can develop at any point during treatment. Severe abdominal pain, nausea, and vomiting warrant immediate medical attention, and if pancreatitis is confirmed, Depakote is typically discontinued.
Common, less serious side effects include nausea, drowsiness, dizziness, tremor, and hair thinning. Many of these improve over time or with dose adjustments. Some people also experience changes in their platelet counts, which can affect blood clotting, so periodic blood work monitors for this as well.
Pregnancy and Reproductive Risks
Depakote poses substantial risks during pregnancy. Children born to mothers taking valproate have significantly elevated rates of major birth defects, including neural tube defects (problems with brain and spinal cord development that can occur very early, often before a person knows they’re pregnant). Beyond structural birth defects, prenatal valproate exposure is linked to lower IQ scores and higher rates of neurodevelopmental conditions including autism and ADHD in children.
Because of these risks, the American Epilepsy Society’s position is that valproate should not be given to women of childbearing potential unless other treatments have failed. If you’re taking Depakote and could become pregnant, effective contraception is essential, and any plans for pregnancy should involve a discussion about switching medications well in advance.
Interactions With Other Bipolar Medications
One of the most clinically important interactions involves lamotrigine, another mood stabilizer frequently prescribed for bipolar disorder. Depakote interferes with how the body breaks down lamotrigine, more than doubling the time it takes to clear the drug from your system. This dramatically increases lamotrigine levels in the blood, which raises the risk of a serious and potentially life-threatening skin reaction called Stevens-Johnson syndrome.
When both medications are used together, the lamotrigine dose needs to be cut in half compared to what would normally be prescribed. This is a well-established interaction that your prescriber will account for, but it’s worth knowing about, especially if you’re seeing multiple doctors or adjusting medications.
Depakote can also interact with other anti-seizure medications, certain blood thinners, and aspirin. Keeping all of your prescribers informed about every medication you take, including over-the-counter drugs, helps avoid dangerous overlaps.